Capravirine (AG1549) in Combination With Viracept and Two NRTIs in HIV Infected Patients Who Failed an Initial NNRTI Containing Regimen

• Status: Completed
• Trial end date: 2004-11-01

Summary

This is a 48 week study that is intended for HIV Infected persons whose first treatment regimen was with a nonnucleoside reverse transcriptase inhibitor (NNRTI) and who are now failing that regimen. They must be currently on their failing regimen to be eligible.

• Phase: Phase 2

Details

• Lead Sponsor: Pfizer
• Treatments: Capravirine; Nelfinavir; Reverse Transcriptase Inhibitors